ERBB2 and breast carcinoma: Recent studies suggest an increasing incidence of CNS metastases in breast cancer, likely due to prolonged survival among metastatic patients, limitations of certain chemotherapies in crossing the blood–brain barrier, and more effective systemic targeted therapies (e.g., Human Epidermal Growth Factor Receptor 2 [HER2] inhibitors).